Hostname: page-component-cb9f654ff-r5d9c Total loading time: 0 Render date: 2025-08-31T14:40:15.847Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacotherapies for treating opioid use disorder

Published online by Cambridge University Press:  08 April 2013

Thomas A. Nguyen ,
Jennie H. Hahn  and
Stephen M. Strakowski
Thomas A. Nguyen*
Affiliation:
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Jennie H. Hahn
Affiliation:
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
Stephen M. Strakowski
Affiliation:
Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
*
*Address for correspondence: Dr. Thomas A. Nguyen, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, 260 Stetson Street, Suite #3200, Cincinnati, OH 45267-0559, USA. (Email nguyent@ucphysicians.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Opioid use disorder (OUD) is a major public health problem in the United States. It has resulted in devastating consequences for people with this condition, including psychosocial and legal problems, in addition to contraction of infectious diseases such as HIV and hepatitis B and C. Furthermore, this disease can cause fatalities from drug overdoses and drug–drug interactions. OUD shatters families and destroys relationships. Effective treatment is crucial in order to curtail the consequences of this condition. The objective of this article is to provide a review of the pharmacotherapies currently being used to treat OUD.

Keywords

Medication treatmentsopioid use disorderspsychotherapytreatmentstypes of treatments

Information

Type
Review Articles
Information
CNS Spectrums , Volume 18 , Issue 6 , December 2013 , pp. 289 - 295
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. http://www.samhsa.gov/data/MSDUH/2k10Results.pdf. Last accessed February 18, 2013.Google Scholar
2.Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health. Nonmedical oxycodone users: a comparison with heroin users. 2005. http://www.oas.samhsa.gov/2k4/oxycodoneH.htm. Last accessed February 18, 2013.Google Scholar
3.Substance Abuse and Mental Health Services Administration. 2010 Tables: dependence, abuse, and treatment. http://www.samhsa.gov/data/NSDUH/2k10ResultsTables/Web/HTML/Sect5peTab1to56.htm#Tab5.22A. Last accessed February 18, 2013.Google Scholar
4.McCabe, SE, West, BT, Morales, M, etal. Does early onset of non-medical use of prescription drugs predict subsequent prescription abuse and dependence? Results from a national study. Addiction. 2007; 102(12): 1920–1930.CrossRefGoogle ScholarPubMed
5.Bart, G. Maintenance medication of opiate addiction: the foundation of recovery. J Addict Dis. 2012; 31: 201–225.CrossRefGoogle ScholarPubMed
6.Kaye, AD, Gervitz, C, Bosscher, HA, etal. Ultrarapid opiate detoxification. Eur Neuropsychopharmacol. 2004; 14: 209–216.Google Scholar
7.Farrell, M, Wodak, A, Gowing, L. Maintenance drugs to treat opioid dependence. BMJ. 2012; 344: 2823–2828.CrossRefGoogle ScholarPubMed
8.Sigmon, S, Bisaga, A, Nunes, E, etal. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012; 38(3): 187–189.CrossRefGoogle ScholarPubMed
9.Lobmaier, P, Gossop, M, Waal, H, etal. The pharmacological treatment of opioid addiction—a clinical perspective. Eur J Clin Pharmacol. 2010; 66: 537–545.CrossRefGoogle ScholarPubMed
10.Subramaniam, GA, Stitzer, MA. Clinical characteristics of treatment-seeking prescription opioids vs. heroin-using adolescents with opioid use disorder. Drug Alcohol Depend. 2009; 101: 13–19.CrossRefGoogle ScholarPubMed
11.National Institute on Drug Abuse. Drugs, brains, and behavior: the science of addiction. NIH Publication #07-5605. Reprinted February 2008. http://www.nida.nih.gov/scienceofaddiction/sciofaddiction.pdf. Accessed February 12, 2013.Google Scholar
12.Clausen, T, Ancheiser, K, Waal, H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008; 94(1–3): 151–157.CrossRefGoogle ScholarPubMed
13.Stancliff, S, Herman, J, Fong, C, etal. Opioid maintenance treatment as a harm reduction tool for opioid dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis. 2012; 31: 278–287.CrossRefGoogle ScholarPubMed
14.Zijlstraf, F, Booij, J, van den Brink, W, etal. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. Eur Neuropsychopharmacol. 2008; 18: 262–270.CrossRefGoogle Scholar
15.Van den Brink, W, Haasen, C. Evidence-based treatment of opioid dependent patients. Can J Psychiatry. 2006; 51: 635–646.CrossRefGoogle ScholarPubMed
16.Wadorf, D. Natural recovery from opiate addiction: some social-psychological processes of untreated recovery. J Drug Issues. 1983; 13(2): 237–280.CrossRefGoogle Scholar
17.Mayet, S, Farrell, M, Ferri, M, etal. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev. 2005; CD004330.Google ScholarPubMed
18.Bao, YP, Liu, ZM, Epstein, DH, etal. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009; 35(1): 28–33.CrossRefGoogle ScholarPubMed
19.Gossop, M. Clonidine and the treatment of the opioid withdrawal syndrome. Drug Alcohol Depend. 1988; 21(3): 253–259.CrossRefGoogle Scholar
20.Seifert, J, Metzner, C, Paetzold, W, etal. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry. 2002; 35(5): 159–164.CrossRefGoogle ScholarPubMed
21.Fingerhood, MI, Thompson, MR, Jasinski, DR. A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Subst Abus. 2001; 22(3): 193–199.CrossRefGoogle ScholarPubMed
22.Linteris, N. Buprenorphine dosing regime in the management of outpatient heroin withdrawal. Drug Alcohol Rev. 2002; 21(1): 39–45.CrossRefGoogle Scholar
23.Colson, J, Standiford, H, Silverman, S. Office-based opioid dependence treatment. Pain Physician. 2012; 15: 231–236.CrossRefGoogle ScholarPubMed
24.Fiellin, DA, O'Connor, PG. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347(11): 817–823.CrossRefGoogle ScholarPubMed
25.Anonymous. The history of methadone. http://www.drug-text.org/library/books/methandbook/history.htm. Last accessed January 26, 2013.Google Scholar
26.Kreek, MJ, Borg, L, Zhou, Y, etal. Relationships between endocrine functions and substance abuse syndromes: heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting opioid agonists used in pharmacotherapy of addiction. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds. Hormones, Brain and Behavior. Vol. 5. San Diego, CA: Academic Press; 2002, pp 781–830.CrossRefGoogle Scholar
27.McCance-Katz, EF, Sullivan, LE, Nallami, S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010; 19: 4–16.CrossRefGoogle ScholarPubMed
28.Martin, JA, Campbell, A, Killip, T, etal. QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. J Addict Dis. 2011; 30: 283–306.CrossRefGoogle ScholarPubMed
29.Stotts, AL, Dodrill, CL, Kosten, TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10(11): 1727–1740.CrossRefGoogle ScholarPubMed
30.Koob, GF, Volkow, ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010; 35: 217–238.CrossRefGoogle ScholarPubMed
31.Ducharme, S, Fraser, R, Gill, K. Update on the clinical use of buprenorphine. Can Fam Physician. 2012; 58: 37–41.Google ScholarPubMed
32.Parran, TV, Aldeman, CA, Merkin, B, etal. Long-term outcomes for office based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010; 106(1): 56–60.CrossRefGoogle ScholarPubMed
33.DHHS. Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Drug addiction treatment act of 2000 (DATA 2000). Title XXXV. Section 3502. http://buprenorphine.samhsa.gov/titlexxxv.html. Last accessed January 21, 2013.Google Scholar
34.Bell, J, Trinh, L, Butler, B, etal. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009; 104: 1193–1200.CrossRefGoogle ScholarPubMed
35.Helms, S, Trescot, AM, Colson, etal. Opioid antagonist, partial agonists and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008; 11(2): 225–235.CrossRefGoogle Scholar
36.Ahmadi, J. Methadone versus buprenoprhine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat. 2003; 24(3): 217–220.CrossRefGoogle Scholar
37.Schuh, KJ, Johanson, CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 1999; 56: 55–60.CrossRefGoogle ScholarPubMed
38.Fudala, PJ, Bridge, TP, Herbert, S, etal. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349: 949–958.CrossRefGoogle ScholarPubMed
39.Kintz, P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001; 121: 65–69.CrossRefGoogle ScholarPubMed
40.Mattick, RP, Ali, R, White, JM, etal. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003; 98: 441–452.CrossRefGoogle ScholarPubMed
41.Moore, BA, Fiellin, DA, Barry, DT, etal. Primary care office-based buprenorphine treatment comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007; 22: 527–530.CrossRefGoogle ScholarPubMed
42.Weiss, RD, Porter, JS, Fiellin, DA, etal. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011; 68: 1238–1246.CrossRefGoogle ScholarPubMed
43.Comer, SD, Sullivan, MA, Vosburg, SK, etal. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010; 105: 709–718.CrossRefGoogle ScholarPubMed
44.Mattick, RP, Kimber, J, Breen, C, etal. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008; 2: CD002207.Google Scholar
45.Jones, H, Johnson, R, Jajinski, D, etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effect on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005; 79: 1–10.CrossRefGoogle ScholarPubMed
46.Berkowitz, BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone, and naloxone. Clin Pharmacokinet. 1976; 1(3): 219–230.CrossRefGoogle ScholarPubMed
47.Machikanti, L, Helm, S, Fellows, B, etal. Opioid epidemic in the United States. Pain Physician. 2012; 15: 9–38.CrossRefGoogle Scholar
48.Fiellin, DA, Moore, BA, Sullivan, LE, etal. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008; 17(2): 116–120.CrossRefGoogle ScholarPubMed
49.Handal, KA, Schauben, JL, Salamone, FR. Naloxone. Ann Emerg Med. 1983; 12(7): 438–445.CrossRefGoogle ScholarPubMed
50.Substance Abuse and Mental Health Services Administration. The facts about naltrexone for treatment of opioid addiction. 2009. http://www.samhsa.gov/shin. Last accessed January 9, 2013.Google Scholar
51.Pfohl, DN, Allen, JI, Atkinson, RL, etal. Naltrexone hydrochloride: a review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986; 67: 66–72.Google ScholarPubMed
52.Schottenfeld, RS, Chawarski, MC, Mazlan, M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomized, double blind, placebo controlled trial. Lancet. 2008; 371(9631): 2192–2200.CrossRefGoogle Scholar
53.Volavka, J, Resnick, RB, Kesterbaum, RS, etal. Short-term effects of naltrexone in 155 heroin ex-addicts. Biol Psychiatry. 1976; 11: 679–685.Google ScholarPubMed
54.Minozzi, S, Amato, L, Vecchi, S, etal. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011; CD001333.CrossRefGoogle ScholarPubMed
55.Krupitsky, E, Nunes, EV, Ling, W, etal. Injectible extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicenter randomized trial. Lancet. 2011; 377: 1506–1513.CrossRefGoogle Scholar
56.Gastfriend, DR. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci. 2011; 1216: 144–166.CrossRefGoogle ScholarPubMed